GLP‑1 treatment in Massachusetts
Who ships GLP-1 medication to Massachusetts, what Medicaid covers, and the telehealth rules that apply.
What the federal data shows for Massachusetts
7,195 clinicians in Massachusetts prescribed Trulicity to Medicare Part D patients in 2024, across 194,200 claims. That is the most-prescribed GLP-1 in the state by prescriber count. Part D covers Medicare only, so the figure is a floor on prescribing in Massachusetts rather than a total.
Massachusetts Medicaid reimbursed $121,160,156.16 for 116,354 GLP-1 prescriptions in Q1 2026, or $1,041.31 per prescription. From CMS State Drug Utilization, fee-for-service and managed care combined. Suppressed cells are excluded, never counted as zero.
1 outsourcing facilities registered with the FDA under section 503B give a Massachusetts address, and 0 of them have no recorded FDA inspection. Registration is a filing, not an approval, and an uninspected facility has not passed an inspection — it has not had one. Each one has a page in the 503B register.
What is on this page
- 8 drug cost pages for Massachusetts, each pairing the state's Medicaid figures with pharmacy acquisition cost
- 7 city pages showing where GLP-1 prescribers practise in Massachusetts
- Every link below is a page for Massachusetts specifically, not a national page filtered to it
- CMS NADACNational Average Drug Acquisition Cost, weekly file
- CMS Medicare Part DPrescriber public use file, by geography and drug
- CMS State Drug UtilizationQuarterly Medicaid prescription and reimbursement data
NADAC figures are pharmacy acquisition costs, not retail prices and not what you will pay. This content is educational and is not medical advice.